LIGAND PHARMACEUTICALS Business Summary

Ligand Pharmaceuticals Inc. operates as a high-margin royalty aggregator and specialty finance platform within the biopharmaceutical sector, generating revenue through tiered royalties, milestone payments, and the sale of its proprietary Captisol® solubility technology. The company’s business model is bifurcated into its Royalty Portfolio—comprising over 100 partnered programs including "hero" assets like Travere’s Filspari and Merck’s Ohtuvayre—and its Technology Platforms, which include Captisol and the Pelican Expression Technology®. By pivoting to an infrastructure-light model, Ligand utilizes approximately $1 billion in deployable capital to acquire economic rights in mid-to-late-stage drug programs, targeting a 23% compound annual growth rate in royalty receipts through 2030. In the competitive landscape, Ligand competes directly with Royalty Pharma, XOMA Corporation, and Halozyme Therapeutics, distinguishing itself by combining a diversified royalty-interest portfolio with proprietary drug-enabling technologies that provide steady material-sales income alongside high-upside royalty streams. The leadership team is spearheaded by CEO Todd Davis, a Navy veteran and Harvard MBA with over 30 years of experience in healthcare financing, notably as a founding partner of HealthCare Royalty Partners. The executive suite is rounded out by Chief Financial Officer Octavio "Tavo" Espinoza, who previously led finance at Receptos and Illumina, and Chief Legal Officer Andrew Reardon, who brings extensive expertise in royalty acquisitions from his tenure at HealthCare Royalty Partners. Governance is provided by a board chaired by Dr. John W. Kozarich and includes prominent directors such as Jason M. Aryeh, founder of JALAA Equities, and Dr. John L. LaMattina, former President of Pfizer Global R&D. This leadership group is backed by significant institutional ownership from BlackRock, Vanguard, and State Street, underscoring the firm's strategic focus on disciplined capital allocation and the aggregation of high-value biopharmaceutical intellectual property.